Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Gilead gets rights to Ono's oral BTK inhibitor

Executive Summary

Ono Pharmaceutical Co. Ltd. granted Gilead Sciences Inc. exclusive rights to co-develop and sell ONO4059, an oral Bruton’s tyrosine kinase (BTK) inhibitor. Gilead can commercialize the compound worldwide, excluding Japan, South Korea, Taiwan, China, and the Association of Southeast Asian Nations (ASEAN), where Ono retains rights.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies